Summary:

- The article discusses a new immunotherapy approach for treating cancer, specifically focusing on the use of chimeric antigen receptor (CAR) T-cell therapy.
- The researchers developed a novel CAR T-cell therapy that targets the CD19 and CD20 antigens, which are expressed on the surface of certain types of cancer cells.
- The study demonstrates promising results in preclinical models, with the CAR T-cell therapy showing effective tumor elimination and prolonged survival in animal models of lymphoma and leukemia.